These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25339844)

  • 41. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
    Asarnow JR; Emslie G; Clarke G; Wagner KD; Spirito A; Vitiello B; Iyengar S; Shamseddeen W; Ritz L; Birmaher B; Ryan N; Kennard B; Mayes T; DeBar L; McCracken J; Strober M; Suddath R; Leonard H; Porta G; Keller M; Brent D
    J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):330-339. PubMed ID: 19182688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study.
    Carton L; Pignon B; Baguet A; Benradia I; Roelandt JL; Vaiva G; Thomas P; Amad A; De Timary P; Naassila M; Geoffroy PA; Rolland B
    Drug Alcohol Depend; 2018 Jun; 187():40-47. PubMed ID: 29626745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of trauma-focused treatment for adolescents with major depressive disorder.
    Paauw C; de Roos C; Tummers J; de Jongh A; Dingemans A
    Eur J Psychotraumatol; 2019; 10(1):1682931. PubMed ID: 31762948
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
    Zhou X; Teng T; Zhang Y; Del Giovane C; Furukawa TA; Weisz JR; Li X; Cuijpers P; Coghill D; Xiang Y; Hetrick SE; Leucht S; Qin M; Barth J; Ravindran AV; Yang L; Curry J; Fan L; Silva SG; Cipriani A; Xie P
    Lancet Psychiatry; 2020 Jul; 7(7):581-601. PubMed ID: 32563306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cognitive-behavioral therapy added to fluoxetine in major depressive disorder after 4 weeks of fluoxetine-treatment: 16-week open label study.
    Maneeton N; Thongkam A; Maneeton B
    J Med Assoc Thai; 2010 Mar; 93(3):337-42. PubMed ID: 20420109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comorbidity between major depression and alcohol use disorder from adolescence to adulthood.
    Brière FN; Rohde P; Seeley JR; Klein D; Lewinsohn PM
    Compr Psychiatry; 2014 Apr; 55(3):526-33. PubMed ID: 24246605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders.
    Riggs PD; Mikulich-Gilbertson SK; Davies RD; Lohman M; Klein C; Stover SK
    Arch Pediatr Adolesc Med; 2007 Nov; 161(11):1026-34. PubMed ID: 17984403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
    Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
    Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antidepressant effectiveness of deep Transcranial Magnetic Stimulation (dTMS) in patients with Major Depressive Disorder (MDD) with or without Alcohol Use Disorders (AUDs): a 6-month, open label, follow-up study.
    Rapinesi C; Curto M; Kotzalidis GD; Del Casale A; Serata D; Ferri VR; Di Pietro S; Scatena P; Bersani FS; Raccah RN; Digiacomantonio V; Ferracuti S; Bersani G; Zangen A; Angeletti G; Girardi P
    J Affect Disord; 2015 Mar; 174():57-63. PubMed ID: 25484178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Online cognitive behavioral therapy for insomnia (CBT-I) for the treatment of insomnia among individuals with alcohol use disorder: study protocol for a randomized controlled trial.
    Brooks AT; Tuason RT; Chakravorty S; Raju S; Ritterband LM; Thorndike FP; Wallen GR
    Pilot Feasibility Stud; 2018; 4():183. PubMed ID: 30555713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of cognitive-behavioral therapy, antidepressants, their combination and standard treatment for Chinese patients with moderate-severe major depressive disorders.
    Zu S; Xiang YT; Liu J; Zhang L; Wang G; Ma X; Kilbourne AM; Ungvari GS; Chiu HF; Lai KY; Wong SY; Yu DS; Li ZJ
    J Affect Disord; 2014 Jan; 152-154():262-7. PubMed ID: 24140226
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Depressive symptoms as a predictor of alcohol relapse after residential treatment programs for alcohol use disorder.
    Suter M; Strik W; Moggi F
    J Subst Abuse Treat; 2011 Oct; 41(3):225-32. PubMed ID: 21546204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PsychotherapyPlus: augmentation of cognitive behavioral therapy (CBT) with prefrontal transcranial direct current stimulation (tDCS) in major depressive disorder-study design and methodology of a multicenter double-blind randomized placebo-controlled trial.
    Bajbouj M; Aust S; Spies J; Herrera-Melendez AL; Mayer SV; Peters M; Plewnia C; Fallgatter AJ; Frase L; Normann C; Behler N; Wulf L; Brakemeier EL; Padberg F
    Eur Arch Psychiatry Clin Neurosci; 2018 Dec; 268(8):797-808. PubMed ID: 29214483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder.
    Grilo CM; Crosby RD; Wilson GT; Masheb RM
    J Consult Clin Psychol; 2012 Dec; 80(6):1108-13. PubMed ID: 22985205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
    Cornelius JR; Clark DB; Bukstein OG; Birmaher B; Salloum IM; Brown SA
    Addict Behav; 2005 Oct; 30(9):1824-33. PubMed ID: 16102905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine.
    Melvin GA; Finnin L; Taffe J; Dudley AL; Klimkeit EI; Gordon MS; Tonge B
    Clin Child Psychol Psychiatry; 2019 Oct; 24(4):892-905. PubMed ID: 30638065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized controlled trial of cognitive behaviour therapy for comorbid post-traumatic stress disorder and alcohol use disorders.
    Sannibale C; Teesson M; Creamer M; Sitharthan T; Bryant RA; Sutherland K; Taylor K; Bostock-Matusko D; Visser A; Peek-O'Leary M
    Addiction; 2013 Aug; 108(8):1397-1410. PubMed ID: 25328957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mirtazapine in Comorbid Major Depression and Alcohol Dependence: An Open-Label Trial.
    Cornelius JR; Douaihy AB; Clark DB; Chung T; Wood DS; Daley D
    J Dual Diagn; 2012 Sep; 8(3):200-204. PubMed ID: 23230395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comorbid social anxiety disorder in patients with alcohol use disorder: A systematic review.
    Oliveira LM; Bermudez MB; Macedo MJA; Passos IC
    J Psychiatr Res; 2018 Nov; 106():8-14. PubMed ID: 30236640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.